Hepatitis E

Categories: Cancer diseases, Gastrointestinal diseases, Genetic diseases, Immune diseases, Infectious diseases, Liver diseases, Rare diseases, Skin diseases

Aliases & Classifications for Hepatitis E

MalaCards integrated aliases for Hepatitis E:

Name: Hepatitis E 12 74 52 54 43 15 71


External Ids:

Disease Ontology 12 DOID:4411
MeSH 43 D016751
SNOMED-CT 67 7111000119109
UMLS 71 C0085293

Summaries for Hepatitis E

Disease Ontology : 12 A viral infectious disease that results in inflammation located in liver, has material basis in Hepatitis E virus, which is transmitted by ingestion of contaminated food. The infection has symptom fever, has symptom fatigue, has symptom loss of appetite, has symptom nausea, has symptom vomiting, has symptom abdominal pain, has symptom clay-colored bowel movements, has symptom dark urine, has symptom joint pain, and has symptom jaundice.

MalaCards based summary : Hepatitis E is related to acute liver failure and hepatic coma, and has symptoms including vomiting, fatigue and fever. An important gene associated with Hepatitis E is AMBP (Alpha-1-Microglobulin/Bikunin Precursor), and among its related pathways/superpathways are Cytokine Signaling in Immune system and Measles. The drugs Aluminum sulfate and Ribavirin have been mentioned in the context of this disorder. Affiliated tissues include liver, kidney and testes, and related phenotypes are cellular and homeostasis/metabolism

Wikipedia : 74 Hepatitis E is inflammation of the liver caused by infection with the hepatitis E virus (HEV); it is a... more...

Related Diseases for Hepatitis E

Diseases in the Hepatitis family:

Hepatitis C Virus Hepatitis a
Hepatitis C Viral Hepatitis
Hepatitis B Hepatitis D
Autoimmune Hepatitis Hepatitis E
Autoimmune Hepatitis Type 2 Autoimmune Hepatitis Type 1

Diseases related to Hepatitis E via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 534)
# Related Disease Score Top Affiliating Genes
1 acute liver failure 31.5 GPT F2 ALB
2 hepatic coma 30.9 GPT F2 ALB
3 guillain-barre syndrome 30.8 TNF CD40LG ALB
4 hepatic encephalopathy 30.5 TNF GPT F2 ALB
5 non-a-e hepatitis 30.5 F2 ALB
6 hepatitis c virus 30.4 IFNG GRB2 GPT DDX58
7 acute kidney failure 30.4 GPT F2 ALB
8 cholecystitis 30.4 GPT F2 ALB
9 hepatitis 30.4 TNF IFNG GRB2 GPT GGT1 F2
10 hepatitis d 30.3 GPT F2 CD40LG
11 hepatorenal syndrome 30.2 GPT F2 ALB
12 liver cirrhosis 30.2 MIR122 GPT GGT1 F2 ALB
13 cryoglobulinemia 30.2 TNF IFNG GPT CD40LG
14 encephalitis 29.9 TNF TLR3 DDX58 CD40LG
15 cholestasis 29.9 TNF GPT GGT1 F2 ALB
16 liver disease 29.9 TNF MIR122 GPT GGT1 F2 ALB
17 infantile liver failure syndrome 1 29.9 GPT F2 ALB
18 immune deficiency disease 29.9 TSG101 TNF IFNG GPT CD40LG
19 hemolytic anemia 29.8 TNF IFNG HPX F2 CD40LG
20 peritonitis 29.8 TNF IFNG F2 ALB
21 disseminated intravascular coagulation 29.8 TNF GPT F2
22 hemophagocytic lymphohistiocytosis 29.8 TNF IFNG GPT
23 leptospirosis 29.8 TNF IFNG F2 CD40LG
24 hepatitis a 29.7 TNF TLR3 IFNG GPT GGT1 F2
25 meningoencephalitis 29.7 TNF TLR3 CD40LG ALB
26 myocarditis 29.7 TNF TLR3 IFNG CD40LG
27 purpura 29.7 TNF IFNG F2 CD40LG
28 latent syphilis 29.7 IFNG CD40LG
29 eclampsia 29.7 TNF F2 ALB
30 acalculous cholecystitis 29.6 GPT F2 CD40LG ALB
31 poliomyelitis 29.6 TNF IFNG CD40LG
32 drug-induced hepatitis 29.6 TNF GPT F2 ALB
33 pneumocystosis 29.6 TNF CD40LG ALB
34 hypersensitivity vasculitis 29.5 TNF CD40LG ALB
35 amebiasis 29.5 TNF CD40LG ALB
36 tick-borne encephalitis 29.5 TLR3 DDX58 ALB
37 newcastle disease 29.5 TNF TLR3 DDX58
38 meningitis 29.5 TNF IFNG CD40LG ALB
39 brucellosis 29.5 TNF IFNG CD40LG
40 acute cholangitis 29.5 GPT GGT1 F2 ALB
41 peripheral nervous system disease 29.4 TNF IFNG GPT CD40LG ALB
42 avian influenza 29.4 TNF ISG15 DDX58
43 pericardial effusion 29.4 GPT F2 CD40LG ALB
44 scrub typhus 29.4 TNF IFNG GPT CD40LG
45 bilirubin metabolic disorder 29.3 GPT GGT1 F2 CD40LG ALB
46 chlamydia 29.3 TNF IFNG CD40LG
47 crimean-congo hemorrhagic fever 29.3 TNF TLR3 GPT DDX58
48 dysentery 29.3 TNF GPT CD40LG ALB
49 diarrhea 29.3 TNF IFNG GPT CD40LG ALB
50 viral encephalitis 29.3 TNF TLR3 DDX58 CD40LG

Graphical network of the top 20 diseases related to Hepatitis E:

Diseases related to Hepatitis E

Symptoms & Phenotypes for Hepatitis E


  • vomiting
  • fatigue
  • fever
  • abdominal pain
  • jaundice
  • dark urine
  • nausea
  • loss of appetite
  • joint pain
  • clay-colored bowel movements

MGI Mouse Phenotypes related to Hepatitis E:

# Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.2 ALB ASZ1 CD40LG DDX58 F2 FYN
2 homeostasis/metabolism MP:0005376 10.18 ALB ASGR1 CD40LG DDX58 F2 FYN
3 endocrine/exocrine gland MP:0005379 10.17 ALB AMBP ASZ1 CD40LG FYN GGT1
4 hematopoietic system MP:0005397 10.14 ASGR1 CD40LG DDX58 F2 FYN GGT1
5 immune system MP:0005387 10.13 ALB ASGR1 CD40LG DDX58 F2 FYN
6 mortality/aging MP:0010768 10.07 ALB ASGR1 CD40LG DDX58 F2 FYN
7 neoplasm MP:0002006 9.7 ALB DDX58 GRB2 IFNG TLR3 TNF
8 renal/urinary system MP:0005367 9.56 ALB CD40LG FYN GGT1 GRB2 HPX
9 reproductive system MP:0005389 9.32 AMBP ASZ1 CD40LG F2 FYN GGT1

Drugs & Therapeutics for Hepatitis E

Drugs for Hepatitis E (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 50)
# Name Status Phase Clinical Trials Cas Number PubChem Id
Aluminum sulfate Approved Phase 4 10043-01-3
Ribavirin Approved Phase 4 36791-04-5 37542
3 interferons Phase 4
4 Interferon-alpha Phase 4
5 Vaccines Phase 4
6 Immunologic Factors Phase 4
7 Antiviral Agents Phase 4
8 Anti-Infective Agents Phase 4
9 Antimetabolites Phase 4
Milk thistle Approved, Experimental, Investigational Phase 2, Phase 3 65666-07-1
Nicotinamide Approved, Investigational Phase 2, Phase 3 98-92-0 936
Folic acid Approved, Nutraceutical, Vet_approved Phase 2, Phase 3 59-30-3 6037
Niacin Approved, Investigational, Nutraceutical Phase 2, Phase 3 59-67-6 938
Thiamine Approved, Investigational, Nutraceutical, Vet_approved Phase 2, Phase 3 59-43-8, 70-16-6 1130
Riboflavin Approved, Investigational, Nutraceutical, Vet_approved Phase 2, Phase 3 83-88-5 493570
16 Sunflower Phase 3
17 Vitamins Phase 2, Phase 3
18 Antioxidants Phase 2, Phase 3
19 Vitamin B Complex Phase 2, Phase 3
20 Thiamin Phase 2, Phase 3
21 Nicotinic Acids Phase 2, Phase 3
22 Folate Phase 2, Phase 3
23 Protective Agents Phase 2, Phase 3
24 silymarin Phase 2, Phase 3
25 Vitamin B9 Phase 2, Phase 3
26 Vitamin B2 Phase 2, Phase 3
27 Vitamin B3 Phase 2, Phase 3
Sofosbuvir Approved Phase 2 1190307-88-0 45375808
Lamivudine Approved, Investigational Phase 2 134678-17-4 60825
Peginterferon alfa-2a Approved, Investigational Phase 2 198153-51-4 5360545
Entecavir Approved, Investigational Phase 2 142217-69-4 153941
32 Dexelvucitabine Investigational Phase 2 134379-77-4
Tenofovir Experimental, Investigational Phase 2 147127-20-6 464205
34 Reverse Transcriptase Inhibitors Phase 2
35 Anti-HIV Agents Phase 2
36 Anti-Retroviral Agents Phase 2
37 Antibodies Phase 2
38 Immunoglobulins Phase 2
39 Antibodies, Blocking Phase 2
Aluminum hydroxide Approved, Investigational Phase 1 21645-51-2
41 Pharmaceutical Solutions Phase 1
Permethrin Approved, Investigational 52645-53-1 40326
Resveratrol Investigational 501-36-0 445154
44 Analgesics, Non-Narcotic
45 Platelet Aggregation Inhibitors
46 Analgesics
47 Anti-Inflammatory Agents
48 Antirheumatic Agents
49 Anti-Inflammatory Agents, Non-Steroidal
50 Liver Extracts

Interventional clinical trials:

(show all 42)
# Name Status NCT ID Phase Drugs
1 Evaluation of Safety and Immunogenicity of Recombinant (E. Coli) Hepatitis E Vaccine(Hecolin®) in Seniors Aged Over 65 Years Completed NCT02189603 Phase 4
2 Safety and Immunogenicity Study of the Recombinant Hepatitis E Vaccine(Escherichia Coli) in Healthy Volunteers Aged Over 65 Years Completed NCT02417597 Phase 4
3 A Study on Immunogenicity of Recombinant Hepatitis E Vaccine (Escherichia Coli) Hecolin® Using Accelerated Vaccination Schedule in Adults (Aged Over 18 Years) Completed NCT03168412 Phase 4
4 Safety and Immunogenicity Study of the Recombinant Hepatitis E Vaccine(Escherichia Coli) Coadministration With Recombinant Hepatitis B Vaccine Completed NCT02584543 Phase 4
5 An Open, Pared Trial of Recombinant Hepatitis E Vaccine (Escherichia Coli) Hecolin® in the Chronic Hepatitis B Patients on the Clinical Stability .( Aged 30 Years or Over) Completed NCT02964910 Phase 4
6 An Randomized, Double-blinded Trial of Recombinant Hepatitis E Vaccine (Escherichia Coli) Hecolin® to Evaluate Lot-to-lot Consistency Completed NCT03365921 Phase 4
7 A Study of Peg-interferon Treatment for Nucleos(t)Ide Analogues Suppressed Chronic Hepatitis B Patients With Low Level Hepatitis Surface Antigen Recruiting NCT04035837 Phase 4 pegylated interferon-alfa
8 An Effectiveness Trial (Phase IV) to Evaluate Protection of Pregnant Women by Hepatitis E Virus (HEV) Vaccine in Bangladesh and Risk Factors for Severe HEV Infection. Active, not recruiting NCT02759991 Phase 4 Hecolin;Hepa-B
9 Randomized Study of Two Treatment Strategies With Ribavirin for Chronic Hepatitis E and Severe Acute Forms Terminated NCT02558114 Phase 4 Ribavirin
10 A Phase 3, Randomized, Double-blind, Placebo (Hepatitis B Vaccine) Controlled Clinical Trial of Recombinant (E. Coli) Hepatitis E Vaccine Unknown status NCT01014845 Phase 3
11 Field Trial of Maternal Influenza Immunization in Asia Unknown status NCT01034254 Phase 3
12 A Phase III Multicenter, Randomized, Double-Blind, Placebo(Hepatitis E Vaccine)Controlled Study to Evaluate the Efficacy, Immunogenicity and Safety of a Recombinant(E.Coli)Human Papillomavirus Bivalent Vaccine in Healthy Women Completed NCT01735006 Phase 3
13 Randomized Trial to Evaluate Mirasol Whole Blood Pathogen Reduction Technology System to Reduce Malaria and Emerging Transfusion Transmitted Infections Recruiting NCT03737669 Phase 3
14 A Multicentre, Double-blind, Randomized, Placebo-controlled, Phase II/III Study to Evaluate the Safety and Efficacy of 280 mg and 420 mg Silymarin TID (Legalon® Capsules) Administered for Four Weeks in Subjects With Acute Viral Hepatitis With a Four Week Follow-up Period Terminated NCT00755950 Phase 2, Phase 3
15 A Double Blind Placebo Controlled Randomized Trial of Ribavirin in Patients With Acute on Chronic Liver Failure Due to Hepatitis E Virus Unknown status NCT01698723 Phase 2 Ribavirin;Placebo
16 HepNet Pilot Trial: Multicenter Trial for the Treatment of Chronic Hepatitis E With Sofosbuvir (SofE) Completed NCT03282474 Phase 2 Sofosbuvir
17 A Phase II, Prospective, Randomized, Double-blind, Placebo Controlled, Field Efficacy Trial of a Candidate Hepatitis E Vaccine in Nepal. Completed NCT00287469 Phase 2
18 A Double-Blind, Randomized Trial of Antiviral Activity and Safety of 12 Weeks Oral Treatment With ACH-126,443 (Beta-L-Fd4C) in Treatment-Naive HBV-Infected Adults Completed NCT00034359 Phase 2 ACH-126, 443 (beta-L-Fd4C);Lamivudine;Placebo
19 Dose-Ranging Study to Evaluate the Safety, Efficacy and Pharmacokinetics of Pegylated Interferon Lambda (BMS-914143) Monotherapy in Interferon-Naive Patients With Chronic Hepatitis B Virus Infection Who Are HBeAg-positive Completed NCT01204762 Phase 2 pegIFN;pegIFNα-2a;PegIFN lambda;Entecavir
20 A Phase 2, Open-label, Randomized, Two-part, Multiple Dose Study Evaluating the Safety, Pharmacokinetics, and Antiviral Efficacy of SB 9200 in Subjects Infected With Chronic Hepatitis B Virus Completed NCT02751996 Phase 2 SB 9200;Placebo;Tenofovir
21 A PhaseⅡ Randomized, Double-Blinded, Placebo Controlled Study to Evaluate the Immunogenicity of the Recombinant (E.Coli) Human Papillomavirus Type 6/11 Bivalent Vaccine in Healthy Volunteers Aged 18-55 Years Active, not recruiting NCT02710851 Phase 2
22 Effectiveness of Adding Standard Plasma or COVID-19 Convalescent Plasma to Standard Treatment, Versus Standard Treatment Alone, in Patients With Recent Onset of COVID-19 Respiratory Failure. A Randomized, Three-arms, Phase 2 Trial Not yet recruiting NCT04428021 Phase 2 Standard Therapy Protocol (STP)
23 A Phase Ib Single Center, Randomized, Blinding, Parallel-controlled Clinical Trial to Evaluate the Safety and Immunogenicity of a Recombinant Hepatitis E Vaccine in Healthy Adults Aged 16 to 65 Years Old in China Completed NCT02603055 Phase 1
24 A Phase 1, Double-Blinded, Placebo Controlled, Clinical Trial to Evaluate the Safety, Reactogenicity, and Immunogenicity of HEV-239 (Hecolin(R)) in a Healthy US Adult Population Recruiting NCT03827395 Phase 1
25 Hepatitis E Virus Infection in Pediatric Transplantation, a Prevalence Study Unknown status NCT02809885
26 Epidemiological Study of Hepatitis E Virus in Maintenance Hemodialysis Patients Unknown status NCT02645955
27 The Epidemiology of Hepatitis E Virus Infection in Israel and Potential Risk Factors, a Multicenter, Comparative, Cross-sectional Study Unknown status NCT02419625
28 Natural Course of Acute Icteric Viral Hepatitis in Type II Diabetes Mellitus Patients and Non-Diabetic Patients:A Pilot Cohort Study Unknown status NCT00689546
29 Investigation of Endemic and Emerging Diseases in Populations of Homeless Households in Marseille. Unknown status NCT02819128
30 Seroprevalence of Hepatitis E in HIV Positive Patients in Basque Country in 2016 (VIhVhEpb): a Prospective Cohort Study Completed NCT02847507
31 Hepatitis E in the Organ Transplant Population Completed NCT02190253
32 Host Responses in Kidney-transplant Recipients With Chronic Hepatitis E Virus Infection Completed NCT01090232
33 Observational Study on Seroprevalence of Hepatitis E Infection in Healthy Blood Donors in the Canton Ticino Completed NCT03601221
34 Role of Cytokines in Hepatitis E Virus Infection During Pregnancy Completed NCT01062321
35 Plasma From Donors Recovered From New Coronavirus 2019 As Therapy For Critical Patients With Covid-19 Completed NCT04321421
36 A Point Prevalence Study to Evaluate the Prevalence of Antibodies to Selected Porcine Viruses in Patients With Cystic Fibrosis Who Are Receiving Porcine-Derived Pancreatic Enzyme Replacement Therapy: A Harmonized Protocol Across Sponsors Completed NCT01858519
37 The Curative Effect and Security of Entecavir Combined Thymosin or Resveratrol on HBeAg Positive Chronic Hepatitis B Patients - a Multi-center, Random, Control, Open Clinical Trial Completed NCT03509688 entecavir+resveratrol;Entecavir;entecavir+thymosin α1
38 The Curative Effect and Security of Interferon Combined Resveratrol on HBeAg Positive Chronic Hepatitis B Patients - a Multi-center, Random, Control, Open Clinical Trial. Completed NCT03546530 Interferon;Interferon+resveratrol
39 Chinese Chronic Liver Failure Consortium Acute-on-Chronic Liver Disease and Failure Study ——a Prospective Multi-center Study in China, the Largest Hepatitis B Virus High-endemic Region. Completed NCT02457637
40 Hepatitis E Infection : Emergence Mechanisms in North-Eastern France of Polymorphic Clinical Forms. Recruiting NCT03524014
41 A Prospective Multi-center Validating Cohort for ACLF Diagnosis and Prognosis From Ch-CANONIC Study Active, not recruiting NCT03641872
42 Hepatitis E Virus Infection Among Patients With Acute Non-A, Non-B, Non-C Hepatitis in Al-Rajhy University Hospital for Liver Not yet recruiting NCT03488589

Search NIH Clinical Center for Hepatitis E

Cochrane evidence based reviews: hepatitis e

Genetic Tests for Hepatitis E

Anatomical Context for Hepatitis E

The Foundational Model of Anatomy Ontology organs/tissues related to Hepatitis E:


MalaCards organs/tissues related to Hepatitis E:

Liver, Kidney, Testes, T Cells, Heart, B Cells, Brain

Publications for Hepatitis E

Articles related to Hepatitis E:

(show top 50) (show all 5126)
# Title Authors PMID Year
Value of hepatitis E virus detection by cell culture compared with nested PCR and serological studies by IgM and IgG. 54 61
19374667 2009
A novel mycovirus that is related to the human pathogen hepatitis E virus and rubi-like viruses. 61 54
19073734 2009
Double-antigen enzyme-linked immunosorbent assay for detection of hepatitis E virus-specific antibodies in human or swine sera. 54 61
18495846 2008
Hepatitis E virus coinfection with hepatotropic viruses in Egyptian children. 54 61
18629421 2008
Active surveillance for acute viral hepatitis in rural villages in the Nile Delta. 54 61
16447107 2006
The 41-amino-acid C-terminal region of the hepatitis E virus ORF3 protein interacts with bikunin, a kunitz-type serine protease inhibitor. 54 61
16140784 2005
Prevalence of hepatitis E virus in Egyptian children presented with minor hepatic disorders. 61 54
17977212 2005
Simultaneous detection of immunoglobulin A (IgA) and IgM antibodies against hepatitis E virus (HEV) Is highly specific for diagnosis of acute HEV infection. 61 54
15634950 2005
Prevalence of antibodies to hepatitis E virus among Japanese blood donors: identification of three blood donors infected with a genotype 3 hepatitis E virus. 61 54
15221899 2004
The ORF3 protein of hepatitis E virus interacts with liver-specific alpha1-microglobulin and its precursor alpha1-microglobulin/bikunin precursor (AMBP) and expedites their export from the hepatocyte. 61 54
15037615 2004
Molecular and serological characterization of sporadic acute hepatitis E in a Japanese patient infected with a genotype III hepatitis E virus in 1993. 54 61
12560575 2003
Clinical and epidemiological relevance of quantitating hepatitis E virus-specific immunoglobulin M. 54 61
12204962 2002
Sero-epidemiology of hepatitis E virus (HEV) in urban and rural children of North India. 54 61
11359972 2001
Diagnostic value of immunoglobulin G (IgG) and IgM anti-hepatitis E virus (HEV) tests based on HEV RNA in an area where hepatitis E is not endemic. 61 54
11060044 2000
[Dynamics of anti-HEV ORF2, ORF3, IgM and IgG in serial sera of patients with hepatitis E and their clinical significance]. 61 54
10923456 1998
Role of immune serum globulins in pregnant women during an epidemic of hepatitis E. 61 54
9658374 1998
[Diagnosis of hepatitis E virus infection in sporadic acute hepatitis]. 54 61
15619831 1997
Acute sporadic hepatitis E virus infection in southern China. 54 61
8550986 1995
Changes of pre-S1 and pre-S2 antigens in sera of patients with hepatitis B virus infection. 54 61
2170220 1990
Presence and persistence of hepatitis E virus RNA and proteins in human bone marrow. 61
32366181 2020
Performance Evaluation of Different Commercial Serological Kits for Diagnosis of Acute Hepatitis E Viral Infection. 61
32548990 2020
Hepatitis E virus genotype 3 in echinoderms: First report of sea urchin (Paracentrotus lividus) contamination. 61
32138985 2020
Hepatitis E: an expanding epidemic with a range of complications. 61
32251845 2020
The global epidemiology of hepatitis E virus infection: A systematic review and meta-analysis. 61
32281721 2020
Individual animal and herd level seroprevalence and risk factors of Hepatitis E in ruminants in Jordan. 61
32147473 2020
Swine hepatitis E virus: Cross-species infection, pork safety and chronic infection. 61
32333941 2020
Absence of hepatitis E virus RNA in semen samples of infertile male in China. 61
31217236 2020
Stability of hepatitis E virus at different pH values. 61
32361052 2020
Hepatitis E Virus Infection in an Italian Cohort of Hematopoietic Stem Cell Transplantation Recipients: Seroprevalence and Infection. 61
32200124 2020
Unexpected long-lasting anti-HEV IgM positivity: Is HEV antigen a better serological marker for hepatitis E infection diagnosis? 61
32106351 2020
[Liver involvement in listeriosis? Think of a hepatitis E virus coinfection]. 61
32241098 2020
Severe Acute Hepatitis E in a Woman with an Autoimmune Background. 61
32504518 2020
Hepatitis E virus infection during pregnancy. 61
32522266 2020
Altered faecal microbiota on the expression of Th cells responses in the exacerbation of patients with hepatitis E infection. 61
32500937 2020
A case of acute liver failure due to hepatitis E virus, liver transplantation, and development of de novo autoimmune hepatitis. 61
32279435 2020
Chronic hepatitis E in an immunocompetent patient. 61
31477532 2020
Hepatitis E: Epidemiology, Clinical Course, Prevention, and Treatment. 61
32389365 2020
Teschovirus and other swine and human enteric viruses in Brazilian watersheds impacted by swine husbandry. 61
31784949 2020
Clinical Outcomes in Patients with Acute Hepatitis E: Exacerbation by Background End-Stage Liver Disease but Not Pure Hepatitis B Virus Infection. 61
31367754 2020
Identification and pathogenicity of a novel genotype avian hepatitis E virus from silkie fowl (gallus gallus). 61
32456826 2020
Evaluation of a non-invasive screening approach to determine hepatitis E virus status of pig farms. 61
32576682 2020
Ribavirin long-term treatment for chronic hepatitis E virus infection in a liver transplant recipient. 61
32553699 2020
A simplified qPCR method revealing tRNAome remodeling upon infection by genotype 3 hepatitis E virus. 61
32133647 2020
The histologic presentation of hepatitis E reflects patients' immune status and pre-existing liver condition. 61
32572157 2020
Development and evaluation of a time-saving RT-qRPA method for the detection of genotype 4 HEV presence in raw pork liver. 61
32203767 2020
HEV superinfection accelerates disease progression in patients with chronic HBV infection and increases mortality in those with cirrhosis. 61
32006586 2020
Development of a rapid technique for extraction of viral DNA/RNA for whole genome sequencing directly from clinical liver tissues. 61
32502499 2020
HCV and HEV: two players in an Egyptian village, a study of prevalence, incidence, and co-infection. 61
32533486 2020
Stable HEV IgG seroprevalence in Belgium between 2006-2014. 61
32564516 2020
Temporal profile of HEV RNA concentration in blood and stool from patients with acute uncomplicated hepatitis E in a region with genotype 1 predominance. 61
31997507 2020

Variations for Hepatitis E

Expression for Hepatitis E

Search GEO for disease gene expression data for Hepatitis E.

Pathways for Hepatitis E

Pathways related to Hepatitis E according to GeneCards Suite gene sharing:

(show all 13)
# Super pathways Score Top Affiliating Genes
Show member pathways
Show member pathways
Show member pathways
Show member pathways
Show member pathways
Show member pathways
7 12.07 TNF TLR3 IFNG DDX58 CD40LG
8 11.89 TNF TLR3 IFNG GRB2
Show member pathways
Show member pathways
11 11.36 TNF IFNG GRB2 FYN
Show member pathways
13 11.28 TNF IFNG CD40LG

GO Terms for Hepatitis E

Cellular components related to Hepatitis E according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.91 TNF ISG15 IFNG HPX F2 CD40LG
2 extracellular exosome GO:0070062 9.81 TSG101 MIR122 HPX GRB2 GPT GGT1
3 extracellular space GO:0005615 9.36 TNF TLR3 MIR122 IFNG HPX GPT
4 blood microparticle GO:0072562 9.26 HPX F2 AMBP ALB

Biological processes related to Hepatitis E according to GeneCards Suite gene sharing:

(show all 24)
# Name GO ID Score Top Affiliating Genes
1 defense response to virus GO:0051607 9.89 TLR3 ISG15 IFNG DDX58
2 leukocyte migration GO:0050900 9.88 TNF GRB2 FYN F2
3 receptor-mediated endocytosis GO:0006898 9.85 HPX ASGR1 AMBP ALB
4 positive regulation of phosphatidylinositol 3-kinase signaling GO:0014068 9.79 TNF FYN F2
5 positive regulation of interleukin-6 production GO:0032755 9.75 TNF TLR3 DDX58
6 T cell costimulation GO:0031295 9.73 GRB2 FYN CD40LG
7 response to virus GO:0009615 9.71 TNF TLR3 IFNG DDX58
8 extrinsic apoptotic signaling pathway GO:0097191 9.69 TNF TLR3 IFNG
9 positive regulation of interleukin-6 secretion GO:2000778 9.67 TNF IFNG DDX58
10 microglial cell activation GO:0001774 9.63 TNF TLR3 IFNG
11 negative regulation of amyloid-beta clearance GO:1900222 9.61 TNF IFNG
12 positive regulation of interleukin-1 beta biosynthetic process GO:0050725 9.61 TNF IFNG
13 positive regulation of interleukin-8 production GO:0032757 9.61 TNF TLR3 DDX58
14 necroptotic signaling pathway GO:0097527 9.6 TNF TLR3
15 detection of virus GO:0009597 9.57 TLR3 DDX58
16 regulation of immunoglobulin secretion GO:0051023 9.54 TNF CD40LG
17 positive regulation of humoral immune response mediated by circulating immunoglobulin GO:0002925 9.52 TNF HPX
18 positive regulation of calcidiol 1-monooxygenase activity GO:0060559 9.48 TNF IFNG
19 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.46 TNF IFNG HPX FYN
20 positive regulation of interleukin-12 production GO:0032735 9.43 TLR3 IFNG CD40LG
21 positive regulation of vitamin D biosynthetic process GO:0060557 9.37 TNF IFNG
22 positive regulation of nitrogen compound metabolic process GO:0051173 9.32 TNF IFNG
23 viral process GO:0016032 9.28 TSG101 TMEM134 ISG15 HPX GRB2 FYN
24 positive regulation of chemokine biosynthetic process GO:0045080 9.13 TNF TLR3 IFNG

Sources for Hepatitis E

9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
31 HPO
32 ICD10
33 ICD10 via Orphanet
37 LifeMap
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
54 Novoseek
57 OMIM via Orphanet
61 PubMed
70 Tocris
72 UMLS via Orphanet
Loading form....